全文获取类型
收费全文 | 715篇 |
免费 | 17篇 |
专业分类
管理学 | 23篇 |
民族学 | 2篇 |
人口学 | 5篇 |
丛书文集 | 9篇 |
理论方法论 | 5篇 |
综合类 | 75篇 |
社会学 | 14篇 |
统计学 | 599篇 |
出版年
2023年 | 2篇 |
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 11篇 |
2019年 | 15篇 |
2018年 | 18篇 |
2017年 | 23篇 |
2016年 | 12篇 |
2015年 | 19篇 |
2014年 | 19篇 |
2013年 | 228篇 |
2012年 | 49篇 |
2011年 | 32篇 |
2010年 | 24篇 |
2009年 | 18篇 |
2008年 | 36篇 |
2007年 | 22篇 |
2006年 | 13篇 |
2005年 | 16篇 |
2004年 | 14篇 |
2003年 | 14篇 |
2002年 | 7篇 |
2001年 | 9篇 |
2000年 | 8篇 |
1999年 | 5篇 |
1998年 | 6篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 5篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 4篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 11篇 |
1984年 | 14篇 |
1983年 | 12篇 |
1982年 | 11篇 |
1981年 | 5篇 |
1980年 | 1篇 |
1979年 | 6篇 |
1978年 | 1篇 |
1977年 | 5篇 |
1976年 | 1篇 |
1975年 | 2篇 |
排序方式: 共有732条查询结果,搜索用时 0 毫秒
731.
Alessandra Serra Pavel Mozgunov Geraint Davies Thomas Jaki 《Pharmaceutical statistics》2023,22(5):938-962
Tuberculosis (TB) is one of the biggest killers among infectious diseases worldwide. Together with the identification of drugs that can provide benefits to patients, the challenge in TB is also the optimisation of the duration of these treatments. While conventional duration of treatment in TB is 6 months, there is evidence that shorter durations might be as effective but could be associated with fewer side effects and may be associated with better adherence. Based on a recent proposal of an adaptive order-restricted superiority design that employs the ordering assumptions within various duration of the same drug, we propose a non-inferiority (typically used in TB trials) adaptive design that effectively uses the order assumption. Together with the general construction of the hypothesis testing and expression for type I and type II errors, we focus on how the novel design was proposed for a TB trial concept. We consider a number of practical aspects such as choice of the design parameters, randomisation ratios, and timings of the interim analyses, and how these were discussed with the clinical team. 相似文献
732.
Recently, the US Food and Drug Administration Oncology Center of Excellence initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. The agency pointed out that the current paradigm for dose selection—based on the maximum tolerated dose (MTD)—is not sufficient for molecularly targeted therapies and immunotherapies, for which efficacy may not increase after the dose reaches a certain level. In these cases, it is more appropriate to identify the optimal biological dose (OBD) that optimizes the risk–benefit tradeoff of the drug. Project Optimus has spurred tremendous interest and urgent need for guidance on designing dose optimization trials. In this article, we review several representative dose optimization designs, including model-based and model-assisted designs, and compare their operating characteristics based on 10,000 randomly generated scenarios with various dose-toxicity and dose-efficacy curves and some fixed representative scenarios. The results show that, compared with model-based designs, model-assisted methods have advantages of easy-to-implement, robustness, and high accuracy to identify OBD. Some guidance is provided to help biostatisticians and clinicians to choose appropriate dose optimization methods in practice. 相似文献